Nobelpharma
This article was originally published in The Gray Sheet
Executive Summary
Will appeal jury verdict on litigation involving Implant Innovations, Inc. (3i) that it fraudulently obtained a patent regarding surface technology on titanium dental implants ("The Gray Sheet" May 16, I&W-9). Nobelpharma "strongly believes that the verdict is wrong, and that it is the result of erroneous rulings made by the Court, including rulings that precluded several of Nobelpharma's witnesses from testifying." The firm notes that in January 1989 Core-Vent signed a consent decree asserting the validity of the same patent at issue in the 3i case. Additional litigation is ongoing between Core-Vent and Nobelpharma, Core-Vent says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.